Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional programme validating the NICE diagnostics guidance pathway throughout a 5.2-million population by West, NP et al.

Lynch syndrome screening in colorectal cancer: results of a
prospective 2-year regional programme validating the NICE
diagnostics guidance pathway throughout a 5.2-million
population
Nicholas P West, Niall Gallop, Danny Kaye, Amy Glover, Caroline Young, Gordon G A
Hutchins, Scarlet F Brockmoeller, Alice C Westwood, Hannah Rossington, Philip Quirke &
the Yorkshire Cancer Research Bowel Cancer Improvement Programme Group
Pathology and Data Analytics, Leeds Institute of Medical Research at St James’s, University of Leeds, Leeds, UK
Date of submission 2 February 2021
Accepted for publication 15 April 2021
Published online Article Accepted 19 April 2021
West N P, Gallop N, Kaye D, Glover A, Young C, Hutchins G G A, Brockmoeller S F, Westwood A C,
Rossington H & Quirke P on behalf of the Yorkshire Cancer Research Bowel Cancer Improvement Programme
Group
(2021) Histopathology. https://doi.org/10.1111/his.14390
Lynch syndrome screening in colorectal cancer: results of a prospective 2-year regional
programme validating the NICE diagnostics guidance pathway throughout a 5.2-million
population
Aims: Screening all patients newly diagnosed with
colorectal cancer (CRC) for possible Lynch syndrome
(LS) has been recommended in the United Kingdom
since the National Institute for Health and Care
Excellence (NICE) released new diagnostics guidance
in February 2017. We sought to validate the NICE
screening pathway through a prospective regional
programme throughout a 5.2-million population dur-
ing a 2-year period.
Methods and results: Pathology departments at 14
hospital trusts in the Yorkshire and Humber region of
the United Kingdom were invited to refer material from
patients with newly diagnosed CRC aged 50 years or
over between 1 April 2017 and 31 March 2019 for LS
screening. Testing consisted of immunohistochemistry
for MLH1, PMS2, MSH2 and MSH6 followed by BRAF
mutation analysis  MLH1 promoter methylation test-
ing in cases showing MLH1 loss. A total of 3141 indi-
vidual specimens were submitted for testing from 12
departments consisting of 3061 unique tumours and
2791 prospectively acquired patients with CRC. Defec-
tive mismatch repair (dMMR) was observed in 15% of
cases. In cases showing MLH1 loss, 76% contained a
detectable BRAF mutation and, of the remainder, 77%
showed MLH1 promoter hypermethylation. Of the
patients included in the final analysis, 81 (2.9%) had
an indication for germline testing.
Conclusion: LS screening using the NICE diagnostics
guidance pathway is deliverable at scale identifying
significant numbers of patients with dMMR. This infor-
mation is used to refer patients to regional clinical
genetics services in addition to informing treatment
pathways including the use of adjuvant/neoadjuvant
chemotherapy and immunotherapy.
Keywords: colorectal cancer, Lynch syndrome, mismatch repair
Address for correspondence: Nicholas P West, Pathology and Data Analytics, Level 4, Wellcome Trust Brenner Building, St James’s Univer-
sity Hospital, Beckett Street, Leeds LS9 7TF, UK. e-mail: n.p.west@leeds.ac.uk
© 2021 The Authors. Histopathology published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
Histopathology 2021 DOI: 10.1111/his.14390
Introduction
Approximately 3% of colorectal cancers (CRC) arise in
the context of Lynch syndrome (LS), where the patient
has a germline mutation in a DNA mismatch repair
(MMR) gene.1 Prior to February 2017, CRC patients
were tested for LS if they were at high risk according to
clinical criteria, e.g. aged under 50 years or with a
strong family history. However, a large proportion of
LS patients were missed by this strategy. LS patients
with CRC are at an increased risk of developing meta-
chronous colorectal and other cancers. After an LS
diagnosis, germline testing is offered to family members
and screening/risk-reducing strategies used to identify
early tumours or prevent their development, thereby
improving outcomes.
The National Institute for Health and Care Excellence
(NICE) issued new diagnostics guidance (DG27) in
February 2017 recommending that all patients with
newly diagnosed CRC be screened for LS.2 The pathway
includes testing tumour tissue for defective MMR
(dMMR) by either microsatellite instability (MSI) testing
or immunohistochemistry (IHC) for the MMR proteins
MLH1, PMS2, MSH2 or MSH6. Tumours showing MSI
or MLH1 loss should subsequently undergo BRAF muta-
tion testing followed by MLH1 promoter methylation
analysis in the absence of a BRAF mutation. Patients
with tumours showing MSH2, MSH6 or isolated PMS2
loss, or MLH1 loss/MSI with no evidence of BRAF muta-
tion/MLH1 promoter hypermethylation, are referred for
germline testing if clinically appropriate.
The Yorkshire Cancer Research Bowel Cancer
Improvement Programme (YCR BCIP) commenced in
2016 with an aim to improve CRC outcomes among
the 16 CRC multidisciplinary teams within 14 NHS
trusts in the Yorkshire and Humber (YH) region of
the United Kingdom, serving a population of 5.2 mil-
lion.3 The programme included funding to implement
LS screening until a point where the service could be
commissioned through the NHS. In this study, we
report the results of this prospective 2-year pro-
gramme as a validation of the DG27 IHC pathway.
Materials and methods
C A S E S F O R T E S T I N G
LS screening was offered to all CRC multidisciplinary
teams in the YH region. All patients diagnosed with
adenocarcinoma of the colon or rectum between 1
April 2017 and 31 March 2019 for whom there was
no routine LS screening pathway already in place were
eligible for testing. It was anticipated that pathways
were in place to screen patients diagnosed under the
age of 50 years following the Royal College of Patholo-
gists 2014 guidance,4 and the programme sought to
not disrupt these established pathways. Participating
centres sent a single formalin-fixed paraffin-embedded
tissue block per unique tumour along with a completed
request form and local histopathology report to the
central laboratory at the University of Leeds. The diag-
nostic biopsy block (or polypectomy if a malignant
polyp) was recommended for testing to reduce the risks
of poor fixation-associated artefacts and effects of
neoadjuvant treatment. However, the resection speci-
men was tested if this was the only specimen with
invasive adenocarcinoma available.
T E S T I N G P A T H W A Y
IHC was performed for the four MMR proteins
(MLH1, PMS2, MSH2 and MSH6) on a Dako Auto-
stainer (Dako, Glostrup, Denmark). Cases showing
loss of MSH2, MSH6 or isolated PMS2 were recom-
mended for germline testing if clinically appropriate.
Cases showing loss of MLH1 underwent BRAF codon
600 mutational analysis by pyrosequencing.5 Cases
undergoing BRAF testing with no evidence of a muta-
tion underwent MLH1 promotor methylation analysis
in the Genetics Laboratory at Leeds Teaching Hospi-
tals NHS Trust. Further details are provided in the
Supporting information.
E T H I C A L A P P R O V A L
Ethical approval was not required, because DG27 was
already in place recommending LS screening in all
patients diagnosed with CRC. Testing was considered
part of the ‘standard of care’ clinical pathway. Speci-
fic patient consent was therefore not obtained.
S T A T I S T I C A L A N A L Y S I S
Categorical variables were compared using Pearson’s
c2 test and continuous variables using the Mann–
Whitney U-test. All analyses were performed using
IBM SPSS Statistics version 23 (IBM, New York, NY,
USA). Statistical significance was defined by any anal-
yses where P < 0.05.
Results
C A S E S
Between 19 May 2017 and 14 May 2019, 3141
individual specimens were submitted for LS screening
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from 12 histopathology departments throughout the
YH region. Eighty specimens consisted of duplicate
samples from the same tumour, e.g. biopsy followed
by resection or two separate resection blocks. In most
cases such duplicate samples were intentional, e.g. to
complete the full testing pathway if the initial sample
was exhausted or if the assay failed. Occasionally,
duplicate samples were submitted in error. The com-
bined results from any duplicate samples were used
for the final analysis.
Of the 3061 unique tumours received for testing,
213 specimens were excluded from the final analysis
(further details provided in the Supporting informa-
tion). In total, 2791 patients with confirmed adeno-
carcinoma of the colon or rectum aged 50 years or
over at diagnosis were screened. Fifty-three of these
patients had synchronous tumours sent for testing
(50 with two separate tumours and three with three
separate tumours) and one had two separate meta-
chronous tumours, resulting in 2848 individual CRCs
tested and included in the final analysis.
A total of 1753 tests were performed on primary
tumour biopsies (61.6%), 923 on primary tumour
resections (32.4%), 153 on polypectomy specimens
(5.4%), five on lymph node metastases (0.2%) and 14
on distant metastases (0.5%).
M I S M A T C H R E P A I R S T A T U S
Immunohistochemistry (IHC) failed to give a definitive
result in seven tumours (0.25%). For the 2841
tumours with a definitive IHC result, 2411 showed
proficient MMR (pMMR) and 430 showed dMMR
(15.1%), including 363 with primary MLH1 loss
(12.8%), 25 with primary PMS2 loss (0.9%), 27 with
primary MSH2 loss (1.0%) and 15 with primary
MSH6 loss (0.5%).
Of the 363 tumours showing loss of MLH1/PMS2,
BRAF and/or MLH1 promoter methylation testing
failed to determine whether the features were proba-
bly in keeping with somatic dMMR in 12 cases (six
due to methylation failure, two due to BRAF failure
and four where no tumour remained after initial
IHC). In these 12 cases, no alternative samples were
available to complete the testing pathway. Of the
other 351 cases showing MLH1/PMS2 loss, 267
(76.1%) demonstrated a BRAF V600E mutation. Of
the 84 tumours with no evidence of BRAF mutation,
65 (77.4%) showed hypermethylation of the MLH1
promotor region.
Of 430 dMMR tumours, 44 (10.2%) showed unu-
sual patterns of protein loss not described in DG27.
These included loss of additional non-paired proteins,
clonal loss and patchy loss (Figure 1). Further details
regarding unusual patterns of protein loss and syn-
chronous/metachronous tumours are provided in the
Supporting information.
R E L A T I O N S H I P B E T W E E N M M R S T A T U S A N D
C L I N I C O P A T H O L O G I C A L V A R I A B L E S
The relationship between MMR status and clinico-
pathological variables is shown in Table 1. When the
dMMR tumours were assessed by the primary protein
lost by IHC, the association with female gender and
older age was only observed in the MLH1 loss cases
(Table 2). A detailed analysis by tumour site showed
that there was a significant difference in the distribu-
tion of pMMR tumours, probably somatic dMMR and
possible germline dMMR (all P < 0.0001, Table 3
and Figure 2). While cases showing MLH1 loss (both
somatic and possible germline) and isolated PMS2
loss were predominantly right-sided, there was a
more even distribution for cases showing MSH2 loss
and a left-sided predominance for isolated MSH6 loss
(Table 2).
R E C O M M E N D A T I O N F O R G E R M L I N E T E S T I N G
Of the cases in the final analysis, 85 (2.98%) tumours
from 81 (2.90%) patients had a definite indication for
germline testing according to DG27. This did not
include cases showing MSH2 and/or MSH6 loss in
the context of MLH1/PMS2 loss with either a BRAF
mutation or MLH1 promoter hypermethylation. A
further six patients were recommended for germline
testing due to failure of MLH1 methylation analysis
in the context of MLH1/PMS2 loss with wild-type
BRAF and no remaining material available to test.
Discussion
This is the largest regional validation study of the
NICE DG27 IHC pathway for LS screening, to our
knowledge, resulting in more than 3000 individual
tumours tested from a 5.2-million population during
a 2-year period. The programme prospectively tested
tumour material from 2791 patients with CRC diag-
nosed at the age of 50 years or more using MMR
IHC as a first-line test followed by BRAF mutational
analysis and MLH1 promoter methylation, as
required.
Two-thirds of cases were tested using diagnostic
biopsy or polypectomy specimens, which represented
the first available sample, and ensured that the MMR
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result was reported to the multidisciplinary team at
an early stage in the treatment pathway. This is
increasingly important for management outside LS
screening, given the better prognosis of dMMR
tumours, relative insensitivity to 5-fluorouracil based
regimens and sensitivity to immunotherapy.7–9 In the
YH region, MMR status forms a key component of
the adjuvant chemotherapy decision-making algo-
rithm,10 and immunotherapy is being considered in
stage IV dMMR, in line with the NHS England
interim treatment options during the COVID-19 pan-
demic.11 We have introduced a neoadjuvant
chemotherapy pathway for advanced operable colon
cancer following the FOxTROT trial, and again MMR
status forms an important component, given the lim-
ited tumour regression and no apparent survival ben-
efit in dMMR tumours.12 Other key advantages of
testing biopsies include avoiding artefacts related to
poor fixation and the neoadjuvant therapy, which




Figure 1. An unusual case at the rectosigmoid junction showing clonal defective mismatch repair (dMMR) (MLH1 and PMS2) in the inva-
sive carcinoma. This was associated with no evidence of BRAF mutation; however, hypermethylation of the MLH1 promoter region was
demonstrated, in keeping with somatic dMMR. A, Overview haematoxylin and eosin (H&E) stain of the multiple biopsy pieces with rectangu-
lar annotation indicating the piece shown at higher magnification. B, Higher magnification H&E stain showing invasive carcinoma. C, Corre-
sponding area stained with MLH1 showing tumour with areas of retained expression (left) and lost expression (right). D, Corresponding area
stained with PMS2 showing tumour with areas of retained expression (left) and lost expression (right). E, Corresponding area stained with
MSH2 showing tumour with retained expression throughout. F, Corresponding area stained with MSH6 showing tumour with retained
expression throughout.
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In the remaining third of cases testing was largely
performed on primary tumour resections, because no
biopsy was taken, biopsy was non-diagnostic, adeno-
carcinoma cut out of the biopsy block or biopsy test-
ing was missed.
IHC was chosen over MSI testing due to the lower
failure rate, ability to test samples with tiny amounts
of tumour (common in biopsies), determine the speci-
fic proteins affected and whether clonal/complete and
rapid turnaround of the result. By contrast, MSI test-
ing generally requires a tumour content of > 20%
(depending on technology), cannot determine the
affected genes (or whether clonal) and requires send-
ing away to a centralised genomics laboratory lead-
ing to significantly increased turn-around times.
Discussion with our regional clinical genetics service
confirms significant value in knowing the probable
gene affected when interrogating the germline for
potential novel mutations. In addition, IHC is readily
available within most histopathology departments
and could be easily rolled out into clinical practice
internationally if resources are identified.
In patients where MMR testing was successful the
dMMR rate was 15.1%, with a recommendation for
germline testing in 2.9% of patients overall. These
data are in keeping with previous studies.14
As expected, the majority of dMMR cases showed
MLH1/PMS2 loss with either a BRAF mutation or
MLH1 promoter hypermethylation, in keeping with
somatic dMMR. Despite this, a number of cases





(n = 430) P-value
Gender
Male 1493 (62.9) 151 (36.1) < 0.0001
Female 879 (37.1) 267 (63.9)
Not stated 39 12
Age (years)
Median 71 76 < 0.0001
IQR 63 to 78 68 to 82
Site
Right side 670 (28.1) 343 (80.7) < 0.0001
Left side 1713 (71.9) 82 (19.3)




2312 (96.1) 388 (90.7) < 0.0001
Mucinous
adenocarcinoma
86 (3.6) 36 (8.4)
Signet ring
cell carcinoma
7 (0.3) 3 (0.7)
Medullary
carcinoma
0 (0.0) 1 (0.2)
Not stated 6 2
Differentiation
Well/moderate 2176 (94.1) 286 (72.6) < 0.0001
Poor 137 (5.9) 108 (27.4)
Not stated 98 36
pT stage
pT1 56 (7.3) 6 (1.4) 0.389
pT2 129 (16.9) 29 (19.9)
pT3 338 (44.2) 69 (47.3)
pT4 240 (31.4) 42 (28.8)
Not stated 1648 284
Tumour size (mm)
Median 38 55 < 0.0001





(n = 430) P-value
pN stage
pN0 408 (54.8) 99 (68.8) 0.007
pN1 212 (28.5) 30 (20.8)
pN2 125 (16.8) 15 (10.4)
Not stated 1666 286
Lymph node yield
Median 18 21 < 0.0001
IQR 13 to 24 15 to 29
Values in parentheses represent percentages. pMMR, proficient
mismatch repair; dMMR, defective mismatch repair; IQR,
interquartile range; NOS, not otherwise specified. Data regarding
stage, tumour size and lymph node yield are restricted to cases
where resection specimens were tested.
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(n = 15) P-value
Gender
Male 107 (30.2) 15 (62.5) 18 (72.0) 11 (73.3) < 0.0001
Female 247 (69.8) 9 (37.5) 7 (28.0) 4 (26.7)
Not stated 9 1 2 0
Age (years)
Median 77 64 62 68 < 0.0001
IQR 70 to 82 60 to 72 56 to 67 61 to 75
Site
Right side 305 (85.2) 19 (76.0) 15 (55.6) 4 (26.7) < 0.0001
Left side 53 (14.8) 6 (24.0) 12 (44.4) 11(73.3)
Not stated 5 0 0 0
Tumour type
Adenocarcinoma NOS 330 (91.4) 23 (92.0) 20 (74.1) 15 (100.0) 0.153
Mucinous adenocarcinoma 27 (7.5) 2 (8.0) 7 (25.9) 0 (0.0)
Signet ring cell carcinoma 3 (0.8) 0 (0.0) 0 (0.0) 0 (0.0)
Medullary carcinoma 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0)
Not stated 2 0 0 0
Differentiation
Well/moderate 239 (71.6) 18 (78.3) 17 (77.3) 12 (80.0) 0.751
Poor 95 (28.4) 5 (21.7) 5 (22.7) 3 (20.0)
Not stated 29 2 5 0
pT stage
pT1 6 (5.0) 0 (0.0) 0 (0.0) 0 (0.0) 0.924
pT2 24 (19.8) 1 (10.0) 3 (25.0) 1 (33.3)
pT3 56 (46.3) 6 (60.0) 5 (41.7) 2 (66.7)
pT4 35 (28.9) 3 (30.0) 4 (33.3) 0 (0.0)
Not stated 242 15 15 12
Tumour size (mm)
Median 55 55 64 30 0.319
IQR 38 to 70 35 to 73 30 to 81 30 to 30
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showed more unusual IHC staining features that are
not clearly defined in the DG27 flowchart, including
cases with clonal loss and co-existing loss of non-
paired proteins. It is important that histopathologists
are aware of these patterns and report them
appropriately to avoid unnecessary referrals for germ-
line testing, with associated costs and distress for the
patient and their family. We have previously
described our approach to cases demonstrating the
‘null phenotype’,15 and a similar approach is required
for all cases showing unusual features based on the
possibility and likelihood of underlying germline ver-
sus somatic origin. Cases showing MLH1/PMS2 loss
with additional clonal MSH6  MSH2 loss in the
context of a BRAF mutation or MLH1 promoter
hypermethylation can be assumed to be entirely
somatic in origin with no further testing required.
Cases with an indication for germline testing in
which there is evidence of co-existing loss of non-
paired proteins do not need further testing; these
should be recommended for clinical genetics referral.
More attention is required in cases showing complete
loss of MLH1/PMS2/MSH6  MSH2 in the context of
a BRAF mutation or MLH1 promoter hypermethyla-
tion. If testing was initially performed on a biopsy
specimen, it is recommended to repeat the IHC on
multiple blocks from the resection to determine
whether the additional loss of MSH6  MSH2 is com-
plete or clonal. If confirmed to be complete, a clinical
genetics referral is recommended due to the small risk
of somatic MLH1 loss occurring on a background of a
germline mutation in MSH2 or MSH6.16
Some authors have previously proposed a reduced
cost approach whereby staining for only two IHC
markers (PMS2 and MSH6) could be performed as an
initial screen.17 However, the presence of patchy
MSH6 loss in 15% of our cases showing complete









(n = 15) P-value
pN stage
pN0 80 (67.2) 6 (60.0) 10 (83.3) 3(100.0) 0.697
pN1 25 (21.0) 3 (30.0) 2 (16.7) 0 (0.0)
pN2 14 (11.8) 1 (10.0) 0 (0.0) 0 (0.0)
Not stated 244 15 15 12
Lymph node yield
Median 22 22 17 16 0.411
IQR 15 to 30 17 to 29 13 to 24 14 to 16
Values in parentheses represent percentages. IQR, interquartile range; NOS, not otherwise specified. Data regarding stage, tumour size and
lymph node yield are restricted to cases where resection specimens were tested.











Caecum 271 (11.4) 94 (28.7) 12 (14.1)
Ascending colon 202 (8.5) 104 (31.7) 21 (24.7)
Hepatic flexure 72 (3.0) 30 (9.1) 6 (7.1)
Transverse colon 123 (5.2) 56 (17.1) 10 (11.8)
Splenic flexure 44 (1.8) 9 (2.7) 8 (9.4)
Descending colon 90 (3.8) 14 (4.3) 9 (10.6)
Sigmoid/
rectosigmoid colon
723 (30.4) 15 (4.6) 7 (8.2)
Rectum 855 (35.9) 6 (1.8) 12 (14.1)
Missing 31 4 0
Values in parentheses represent percentages. pMMR, proficient
mismatch repair; dMMR, defective mismatch repair. Probable
somatic dMMR was defined as tumours showing MLH1/PMS2 loss
with either a BRAF mutation or MLH1 promoter hypermethylation.
Possible germline dMMR was defined as all cases in which a rec-
ommendation for germline testing was made in the final report.
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cautiously, especially where patchy staining might be
interpreted as an artefact. Similarly, in patients with
multiple tumours, testing only one tumour may miss
dMMR in 11% of cases, although none of these cases
showed features suggestive of germline origin.
The relationship between dMMR and key clinico-
pathological variables has previously been described,
and we confirmed these known associations in our
population.18 There were key differences between
dMMR cases showing probably somatic and possible
germline origin, with those recommended for germ-
line testing being younger, more likely to be male
and evenly distributed around the large bowel. How-
ever, there were significant differences between the
patterns of protein loss with regard to tumour site,
specifically with MSH6 deficient cancers being more
likely to be left-sided.
One of our key objectives was to engage with local
commissioners to migrate testing to the routine clini-
cal service. Despite DG27 being in place, it was
shown in 2018 that only 17% of hospitals were
screening all cases largely due to inadequate
resources in histopathology.19 While screening all
patients at diagnosis is cost-effective, the savings may
take several years to materialise and money often
needs to move between budgets to ensure that
histopathology departments are adequately resourced.
While DG27 recognises the clinical and cost-
effectiveness of screening all CRC patients for LS, it
does not highlight the additional clinical and finan-
cial benefits of identifying somatic dMMR. Good
engagement with our local Cancer Alliances during
the programme enabled testing to migrate to the rou-
tine service from 1 April 2019.
With funding and capacity being a key limitation
internationally, the possibility of low-cost high-
throughput technologies may be of benefit. Artificial
intelligence applied to digitally scanned H&E slides
has been shown to accurately predict dMMR with
95% sensitivity.20,21 Digital pathology is increasingly
used in routine practice, thus the costs are antici-
pated to be minimal, if validated for clinical practice.
Others have proposed a low-cost next-generation
sequencing approach to MSI detection with the inclu-
sion of BRAF testing to streamline the pathway.22
There are some recognised limitations within our
programme. Hospitals joined the programme at vari-
ous times, with some taking several months to submit
cases. A small number did not submit any cases for
testing. Other centres commenced testing in-house or
at an alternative external centre before the pro-
gramme completed. Thus, a number of CRCs diag-
nosed across the region were not tested through the
programme. Based on the expected number of can-
cers, it is estimated that 42% of all newly diagnosed
CRC cases were tested through the programme. Sec-
ondly, we did not have consent to collect data regard-
ing the number of patients referred for germline
testing and the results. Thus, we do not know the
number of new LS patients detected directly through
the programme or indirectly through testing family
members.
In conclusion, we have shown through a prospec-



































Figure 2. The distribution of cases within the large bowel showing proficient mismatch repair (pMMR) and defective mismatch repair
(dMMR) according to whether the cause was likely to be somatic or possible germline in origin. Probable somatic dMMR was defined as
tumours showing MLH1/PMS2 loss with either a BRAF mutation or MLH1 promoter hypermethylation. Possible germline dMMR was
defined as all cases in which a recommendation for germline testing was made in the final report.
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population during a 2-year period that the NICE diag-
nostics guidance DG27 for LS screening in CRC is
deliverable at scale, with more than 3000 tumours
centrally tested, identifying 15% of patients with
dMMR and 2.9% requiring germline testing. In addi-
tion to screening for LS, the results are being used to
inform treatment pathways, including the use of
chemotherapy in the adjuvant/neoadjuvant setting
and the use of immunotherapy in stage IV. We have
shown that such a programme can be undertaken in
routine clinical practice following engagement with
local commissioners through the Cancer Alliances to
ensure that histopathology departments are ade-
quately funded and resourced.
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